ArticleThe veterinary quarterly2025
Longitudinal study on SARS-CoV-2 antibody responses in companion animals, Chile.
Article in The veterinary quarterly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence, Clinical Signs, Diagnosis and Treatment of Post-Pandemic SARS-CoV-2 Infection in Cats in 2023: Co-Infection with FHV, FCV,Veterinary sciences · 2026Article
- SARS-CoV-2 exposure in dogs before and after the largest COVID-19 wave in rural Guatemala, 2022.One health (Amsterdam, Netherlands) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 infection susceptibility in dogs and cats has been documented, with identified risk factors contributing to transmission dynamics. Understanding viral prevalence and the evolution of emerging variants across pandemic waves can clarify the potential role of pets as reservoirs. This study evaluated 3298 serum samples (1921 dogs, 1377 cats) collected from 2020 to 2024. Samples were analyzed using ELISA and viral neutralization assays, revealing a positivity rate of 2.7%. We assessed neutralizing antibody titers (nAbs) against the Wuhan-Hu-1 and Omicron BA.1 strains, finding higher titers in felines compared to canines. A marked reduction in samples exceeding the detection limit was observed after November 2022. Longitudinal data from up to 30 months in a dog and 15 months in two cats demonstrated sustained antibody responses, with increased nAb titers in 7 of 14 monitored animals. Multivariable logistic regression of 275 samples indicated that a pet's vaccination status was associated with an increased risk of infection, while spring season, the owner's number of COVID-19 vaccinations, and the owner's vaccination status were protective factors. These results emphasize the significance of vaccination strategies for both human and animal health, supporting the One Health approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.